The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
May 31st 2024
The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.